AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

The data are being presented today and Friday in poster sessions, including a late-breaking poster p

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consens

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 t

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent incre

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy

ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designatio

Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies t

Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improveme

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo,

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-f

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel pept

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.21) per share which beat the analyst consens

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a pot

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy

Oral presentation to highlight 24-week efficacy and safety dataPoster to feature results of AI-based

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy

This whale alert can help traders discover the next big trading opportunities. Whales are entities w